Physician profile
Daniel C Mausner
NPI 1912907882
$1,602.79
in general payments reported to CMS, 2019-2025
19 companies · $930 in 2025
The $930 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $37.49 · 2022: $73.10 · 2023: $42.93 · 2024: $520 · 2025: $930.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,492.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $530.91 | 2024-2025 | Rezdiffra |
| Novo Nordisk INC | $263.16 | 2024-2025 | Wegovy, Saxenda |
| Abbvie INC. | $196.36 | 2022-2025 | |
| Lilly USA, LLC | $90.03 | 2024-2025 | Jardiance, Zepbound, Mounjaro |
| Aimmune Therapeutics, INC. | $72.88 | 2024 | |
| Merck Sharp & Dohme LLC | $62.91 | 2019-2025 | Gardasil 9, Capvaxive |
| Bayer Healthcare Pharmaceuticals INC. | $48.86 | 2025 | |
| Celgene Corporation | $48.22 | 2022 | |
| Intercept Pharmaceuticals, INC. | $41.25 | 2023-2025 | Ocaliva |
| Renalytix Ai, INC. | $34.89 | 2024 | Kidneyintelx Blood Collection Convenience Kit |
| Genzyme Corporation | $27.12 | 2024 | |
| Janssen Biotech, INC. | $26.59 | 2025 | Tremfya |
| Daiichi Sankyo INC. | $26.15 | 2025 | Injectafer |
| Ipsen Biopharmaceuticals, INC | $24.98 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $24.91 | 2025 | Dupixent |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $23.69 | 2024 | Cologuard Collection Kit |
| Esperion Therapeutics, INC. | $21.39 | 2024 | Nexletol |
| Amgen INC. | $20.18 | 2024 | Repatha |
| Nestle Healthcare Nutrition INC. | $18.31 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Mausner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.